To appreciate the TAT of EGFR genotyping from the tumor sample to the initiation of EGFR-TKI treatment according to the NGS or IdyllaTM method, we then measured the timeframe between (1) tumor sampling and EGFR genotyping request, (2) EGFR genotyping request and result, (3) tumoral sampling and EGFR genotyping result, (4) results from both techniques, and (5) tumoral sampling and initiation of treatment (Figure 2). This evidence concerns the gene EGFR and neoplasm.